BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 26475053)

  • 1. Future directions in the diagnosis and medical treatment of adrenocortical carcinoma.
    Creemers SG; Hofland LJ; Korpershoek E; Franssen GJ; van Kemenade FJ; de Herder WW; Feelders RA
    Endocr Relat Cancer; 2016 Jan; 23(1):R43-69. PubMed ID: 26475053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contemporary management of adrenocortical carcinoma.
    Zini L; Porpiglia F; Fassnacht M
    Eur Urol; 2011 Nov; 60(5):1055-65. PubMed ID: 21831516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update in adrenocortical carcinoma.
    Fassnacht M; Kroiss M; Allolio B
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4551-64. PubMed ID: 24081734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
    Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
    Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adrenocortical carcinoma.
    Baudin E;
    Endocrinol Metab Clin North Am; 2015 Jun; 44(2):411-34. PubMed ID: 26038209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitotane treatment for adrenocortical carcinoma: an overview.
    De Francia S; Ardito A; Daffara F; Zaggia B; Germano A; Berruti A; Di Carlo F
    Minerva Endocrinol; 2012 Mar; 37(1):9-23. PubMed ID: 22382612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis, treatment and outcome of adrenocortical cancer.
    Mihai R
    Br J Surg; 2015 Mar; 102(4):291-306. PubMed ID: 25689291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adrenocortical cancer (ACC) - literature overview and own experience.
    Dworakowska D; Drabarek A; Wenzel I; Babińska A; Świątkowska-Stodulska R; Sworczak K
    Endokrynol Pol; 2014; 65(6):492-502. PubMed ID: 25554619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on adrenocortical carcinoma management and future directions.
    Varghese J; Habra MA
    Curr Opin Endocrinol Diabetes Obes; 2017 Jun; 24(3):208-214. PubMed ID: 28277340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adrenocortical carcinoma and its treatment].
    Tupikowski W; Bednarek-Tupikowska G; Florczak A
    Postepy Hig Med Dosw (Online); 2004 Feb; 58():27-36. PubMed ID: 15069374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing treatment for adrenocortical carcinoma.
    Kerkhofs TM; Ettaieb MH; Hermsen IG; Haak HR
    Endocr Relat Cancer; 2015 Dec; 22(6):R325-38. PubMed ID: 26259571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.
    Calabrese A; Basile V; Puglisi S; Perotti P; Pia A; Saba L; Berchialla P; Porpiglia F; Veltri A; Volante M; Reimondo G; Berruti A; Terzolo M
    Eur J Endocrinol; 2019 Jun; 180(6):387-396. PubMed ID: 30991359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adrenocortical cancer treatment.
    Patalano A; Brancato V; Mantero F
    Horm Res; 2009 Jan; 71 Suppl 1():99-104. PubMed ID: 19153517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
    Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB
    Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of adrenocortical carcinoma.
    Strosberg JR; Hammer GD; Doherty GM
    J Natl Compr Canc Netw; 2009 Jul; 7(7):752-8; quiz 759. PubMed ID: 19635227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adrenocortical carcinoma. Diagnostic work-up and treatment].
    Johanssen S; Fassnacht M; Brix D; Koschker AC; Hahner S; Riedmiller H; Allolio B
    Urologe A; 2008 Feb; 47(2):172-81. PubMed ID: 18030443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical review: Adrenocortical carcinoma: clinical update.
    Allolio B; Fassnacht M
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2027-37. PubMed ID: 16551738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation therapies for adrenocortical carcinoma.
    Altieri B; Ronchi CL; Kroiss M; Fassnacht M
    Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101434. PubMed ID: 32622829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
    Zancanella P; Pianovski MA; Oliveira BH; Ferman S; Piovezan GC; Lichtvan LL; Voss SZ; Stinghen ST; Callefe LG; Parise GA; Santana MH; Figueiredo BC
    J Pediatr Hematol Oncol; 2006 Aug; 28(8):513-24. PubMed ID: 16912591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study.
    Weigand I; Altieri B; Lacombe AMF; Basile V; Kircher S; Landwehr LS; Schreiner J; Zerbini MCN; Ronchi CL; Megerle F; Berruti A; Canu L; Volante M; Paiva I; Della Casa S; Sbiera S; Fassnacht M; Fragoso MCBV; Terzolo M; Kroiss M
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32449514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.